This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Landsburg DJ , Barta SK , Ramchandren R , Batlevi C , Iyer S , Kelly K , Micallef IN , Smith SM , Stevens DA , Alvarez M , Califano A , Shen Y , Bosker G , Parker J , Soikes R , Martinez E , von Roemeling R , Martell RE , Oki Y
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Br J Haematol. 2021 Aug 2
PMID: 34341990 URL: https://www.ncbi.nlm.nih.gov/pubmed/34341990
AbstractFimepinostat (CUDC-907), a first-in-class oral small-molecule inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high-grade B-cell lymphomas (DLBCL/HGBL), particularly those with increased MYC protein expression and/or MYC gene rearrangement/copy number gain (MYC-altered disease). Therefore, a phase 2 study of fimepinostat was conducted in this patient population with 66 eligible patients treated. The primary end-point of overall response (OR) rate for patients with MYC-IHC ≥40% (n = 46) was 15%. Subsequently, exploratory pooled analyses were performed including patients treated on both the phase 1 and 2 studies based upon the presence of MYC-altered disease as well as a biomarker identified by Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER). For these patients with MYC-altered disease (n = 63), the overall response (OR) rate was 22% with seven responding patients remaining on treatment for approximately two years or longer, and VIPER yielded a three-protein biomarker classification with positive and negative predictive values of ≥85%. Prolonged durations of response were achieved by patients with MYC-altered R/R DLBCL/HGBL treated with single-agent fimepinostat. Combination therapies and/or biomarker-based patient selection strategies may lead to higher response rates in future clinical trials.
Notes1365-2141 Landsburg, Daniel J Orcid: 0000-0002-5077-4181 Barta, Stefan K Ramchandren, Radhakrishnan Batlevi, Connie Iyer, Swaminathan Kelly, Kevin Micallef, Ivana N Smith, Sonali M Stevens, Don A Alvarez, Mariano Califano, Andrea Shen, Yao Bosker, Gideon Parker, Jefferson Soikes, Raul Martinez, Elizabeth von Roemeling, Reinhard Martell, Robert E Oki, Yasuhiro Curis, Inc/ Journal Article England Br J Haematol. 2021 Aug 2. doi: 10.1111/bjh.17730.